DURECT Corporation - Special Call Transcript

Aug 27, 2020 / 03:00PM GMT
Eliana Rachel Merle - Cantor Fitzgerald & Co., Research Division - Former Research Analyst

All right. It looks like it's mostly there. Hi everyone. I'm Ellie Merle. I'm one of the biotech analysts here at Cantor. Very happy to have DURECT Corporation with us here today to talk about their programs in alcoholic hepatitis, a range of other liver diseases as well as COVID as well as discuss POSIMIR for post-surgical pain. Very happy to have with us here today James Brown, President and Chief Executive Officer; Michael Arenberg, Chief Financial Officer; and WeiQi Lin, Executive Vice President of Research & Development and Principal Scientist. Thank you guys so much for joining us. Really appreciate the time.

Questions and Answers:

Eliana Rachel Merle - Cantor Fitzgerald & Co., Research Division - Former Research Analyst

And I guess to kick it off, maybe just to sort of frame the discussion for background, you guys have a sort of long corporate history focused on drug delivery devices. And now you're developing DUR-928, which is a novel epigenetic
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot